{
    "2019-04-30": [
        [
            {
                "time": "2019-04-30",
                "original_text": "Health Care Sector Update for 04/30/2019: LLY, PFE, NVS, JNJ, ABTX, MRK, AMGN",
                "features": {
                    "keywords": [
                        "LLY",
                        "PFE",
                        "NVS",
                        "JNJ",
                        "ABTX",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y",
                "features": {
                    "keywords": [
                        "INCY",
                        "Q1",
                        "Earnings",
                        "Beat",
                        "Estimates",
                        "Up",
                        "Y/Y"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Novartisâ€™s Oncology Business Continues Its Strong Showing in Q1",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Oncology",
                        "Business",
                        "Strong",
                        "Showing",
                        "Q1"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "oncology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?",
                "features": {
                    "keywords": [
                        "INCY",
                        "Q1",
                        "Earnings",
                        "Beat"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?",
                "features": {
                    "keywords": [
                        "synthetic lethality",
                        "cancer-fighting",
                        "biotech",
                        "IPO"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-30",
                "original_text": "Biotech Stocks for a Long-Lived Portfolio",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Stocks",
                        "Long-Lived",
                        "Portfolio"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}